Loading stock data…
Can-Fite BioPharma Ltd (CANF)
$2.29+0.06 (+2.69%)
Market ClosedLast close Sep 8
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Can-Fite BioPharma Ltd. in the Healthcare sector is trading at $2.29 with a market capitalization of $6M. Wall Street consensus targets $8.00 (1 analysts), implying a +249.3% move over the next 12 months. The stock is currently near its 52-week low of $2.23, remaining 40.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 13 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +249.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 13) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $155,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | -$1.83M |
| Net Income | — | — | — | — | -$1.65M |
Peer Comparison
JNJUNHPFE
Fundamentals
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead dru...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-136.52%
Volume
Today's trading volume
167,843
Recent News
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations. • Can Fite Biopharma stock is at significant support. What is going on with CANF? Phase 3 Liver Cancer Trial Progress The clinical-stage biotechnology company observed longer-than-expected blinded overall survival in its ongoing pivotal Phase 3 trial evaluating Namodenoson for advanced hepatocellular carcinom
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and t
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat
Sector Update: Health Care Stocks Lower in Friday Afternoon Trading
Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H